Monoclonal antibody with recombinant human hyaluronidase

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

0 marketed 2 in Phase 3

This page covers all Monoclonal antibody with recombinant human hyaluronidase drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD38, CD20.

Targets

CD38 · CD20

Phase 3 pipeline (2)

Daratumumab/rHuPH20 · Masonic Cancer Center, University of Minnesota · Oncology
Daratumumab is a monoclonal antibody that targets CD38 on multiple myeloma cells, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous delivery by breaking down hyaluronic acid in the extracellular matrix.
Rituximab and Hyaluronidase Human · National Cancer Institute (NCI) · Oncology, Immunology
Rituximab targets CD20 on B cells to deplete them, while hyaluronidase enables subcutaneous delivery by breaking down hyaluronic acid in subcutaneous tissue.

Patent intelligence

monoclonal antibody with recombinant human hyaluronidase patent landscape — aggregated cliff calendar, attackable patents, originator estates